Sarah East Brumana, PA
Medical · Roswell, NMNPI 1912235201
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,569 of the $4,925 with a category attached, or 72.5%. 24 manufacturers reported payments, led by Axonics, Inc. at 50.4% of the total. Reporting peaked in 2022 at $2,469 and has fallen 83.1% since, to $416 in 2025. Among medical clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- AbbVie$678
- Merz North America, Inc.$349
- Lilly USA, LLC$262
- Bayer$219
- Amgen$149
- plus $786 from 18 others
What the payments were for
- Travel & lodging$1,35628%
- Food & beverage$3,56972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 32 | $2,483 |
| AbbVie | 52 | $678 |
| Merz North America, Inc. | 6 | $349 |
| Lilly USA, LLC | 17 | $262 |
| Bayer | 12 | $219 |
| Amgen | 8 | $149 |
| Boehringer Ingelheim | 1 | $117 |
| Xeris Pharmaceuticals, Inc. | 5 | $85 |
| Novartis | 5 | $83 |
| Novo Nordisk | 5 | $78 |
| Boston Scientific | 2 | $57 |
| Johnson & Johnson | 3 | $57 |
| GSK | 3 | $43 |
| Medtronic | 1 | $41 |
| AstraZeneca | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Astellas Pharma US Inc | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Abbott | 1 | $23 |
| Merck | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,925 in reported general payments places this provider in the 95th percentile of 156 medical providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 124 | $140,807 |
| OzempicSemaglutide | 99 | $108,213 |
| TrulicityDulaglutide | 48 | $54,585 |
| JanuviaSitagliptin Phosphate | 43 | $47,852 |
| XareltoRivaroxaban | 42 | $46,746 |
| LinzessLinaclotide | 59 | $42,309 |
| EliquisApixaban | 47 | $36,545 |
| RybelsusSemaglutide | 11 | $29,146 |
| FarxigaDapagliflozin Propanediol | 24 | $22,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $18,826 |
| TradjentaLinagliptin | 17 | $15,700 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $11,578 |
| MyrbetriqMirabegron | 11 | $11,558 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $10,034 |
| SteglatroErtugliflozin Pidolate | 11 | $9,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $117 | $164,323155 claims |
| Novo NordiskOzempic, Rybelsus | $78 | $137,359110 claims |
| MerckJanuvia, Steglatro | $18 | $57,61254 claims |
| Lilly USA, LLCTrulicity | $262 | $54,58548 claims |
| Johnson & JohnsonXarelto | $57 | $46,74642 claims |
| AbbVieLinzess, Synthroid | $678 | $45,357119 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $38 | $40,80653 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $43 | $30,40537 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $11,55811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 medical providers in New Mexico.
Other medical in Roswell
- Dawn KorfRoswell$3K
- Amber StollRoswell$576
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
- Loretta GonzalesAlbuquerque$5K
- Ruben FrancoAlbuquerque$4K
- Bradford GwytherAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.